5 U.S. Cannabis Stock Markets to Invest in This Year

Regulatory momentum, improving balance sheets, and the expected effects of federal rescheduling have shifted investor attention away from hype cycles and toward something unfamiliar in cannabis finance: fundamentals.

What’s emerging isn’t just a collection of speculative tickers, but a set of distinct cannabis market sectors, each responding differently to regulatory change and consumer growth.

High Hopes and Fewer Half-Finished Sandwiches

If relief from Section 280E tax treatment materializes alongside Schedule III rescheduling, operators could see meaningful improvements in profitability. Combined with cautious institutional interest returning to the space, cannabis equities are increasingly discussed as infrastructure plays rather than short-term speculation.

For investors considering exposure, here are five areas of the industry shaping the cannabis stock conversation in 2026.

1. The Multi-State Operators (MSOs)

In a regulated industry, scale tends to win. Consolidation across U.S. cannabis markets has left several large operators controlling vertically integrated operations—cultivation, processing, and retail—particularly in limited-license states such as Florida, New York, and Pennsylvania.

• Green Thumb Industries (GTBIF): Often cited by analysts as one of the sector’s more financially disciplined operators, Green Thumb has reported multiple years of positive adjusted earnings while expanding its Rise dispensary network.
• Trulieve Cannabis (TCNNF): A dominant presence in Florida’s medical cannabis market, Trulieve built its position through early licensing advantages and aggressive retail expansion, now operating one of the largest store networks in the U.S. cannabis industry.
• Why investors watch this segment in 2026: If federal tax rules change, MSOs may finally deduct ordinary business expenses—something most industries take for granted. Analysts have suggested this could materially improve margins, although timelines remain dependent on federal implementation.

2. The Landlords: Cannabis REITs

Not every cannabis investment involves growing plants. Some investors prefer owning the buildings instead.

• Innovative Industrial Properties (IIPR): IIPR purchases cultivation and processing facilities and leases them to licensed operators under long-term agreements. Its dividend yield has periodically stood well above traditional REIT averages, reflecting both income potential and sector risk.
• Investment logic: Licensed cultivation requires specialized infrastructure, and access to traditional banking and real estate financing remains uneven. That gap has allowed cannabis-focused REITs to occupy a niche similar to early infrastructure financiers.

3. The “Picks and Shovels” (Ancillary Tech)

History suggests the most consistent profits during a gold rush often come from selling equipment rather than mining itself.

• Turning Point Brands (TPB): Owner of legacy rolling paper brand Zig-Zag, Turning Point benefits from broader consumer participation trends rather than wholesale cannabis pricing cycles.
• WM Technology (MAPS): Operator of the Weedmaps marketplace, WM Technology provides listing, discovery, and digital infrastructure for licensed retailers. As online ordering expands across regulated markets, platforms aggregating consumer data have become an important—though still evolving—part of the ecosystem.

4. The Rescheduling Play: Cannabis Biotech

Federal rescheduling discussions have once again put cannabinoid research companies on investors’ radar. Easing regulatory barriers could streamline clinical trial approvals, opening the door to a broader wave of studies examining cannabinoids across medical and therapeutic fields.

• Focus: Investors are closely watching firms working in metabolic health, pain management, and sleep disorders. As industry narratives expand beyond recreational use, growing interest is emerging around cannabinoids’ potential role in areas such as obesity treatment (including GLP-1 combination therapies), sleep support, and chronic condition management.
• Warning: Drug development moves slowly and burns capital quickly. Clinical outcomes remain uncertain, regulatory pathways are complex, and success rates in biotech are historically low—placing this segment firmly in high-risk territory compared with plant-touching operators or consumer-facing cannabis brands.

5. Consumer Packaged Goods (CPG) Exposure

Another closely watched theme is the gradual overlap between cannabis and mainstream consumer goods.

• Tilray Brands (TLRY): Tilray has expanded into craft beer and non-alcoholic beverage categories alongside its cannabis operations, positioning itself more broadly as a consumer packaged goods company. Some investors speculate that diversified operators could become acquisition targets if federal legalization eventually enables large multinational entry—though such outcomes remain hypothetical for now.

Read more from Soft Secrets:

• Legalization’s Social Impact: Jobs & Economy
• Top Cannabis Stocks to Watch in the U.S. and Canada
• Is Michigan’s Cannabis Boom Turning Into a Bust?

Financial Disclaimer: This article is provided for informational purposes only and does not constitute financial or investment advice. Cannabis stocks remain volatile, and regulatory developments are subject to change. Always conduct your own research and invest only what you can afford to lose.